Cetilistat, a next-generation lipase inhibitor, shows comparable weight loss to orlistat (−4.1% vs. −3.9%) with superior tolerability and greater reductions in TNF-α, positioning it as a potential first-line option for obesity-related intestinal inflammation [68]. This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.